Goldman Sachs raised the target on their Conviction Buy ALXN to $105. The New England Journal of Medicine published 3 compelling case studies of Soliris in treating MPGN, showing that it will very likely succeed in MPGN & increases the probability of success in other complement mediated disorders. MPGN data could be a trigger for a faster approval for multiple rare kidney indications. This represents increasing potential for Soliris. Goldman incerased their 2015--2020 growth rates as a result.
Yeah, even NEJM gives a helping hand to pumping efforts of JPM GS and the bunch. Problem is ALXN does not have any clinical trials for MPGN. There is an investigator initiated phase 1 at Columbia Uni for C3 nephropathy. But the case reports on NEJM are C5 mediated. How is all that stuff going to add up to $20B I would like to ask JPM or GS?